evaluating the costs of a treatment begs the question: why assess a treatment economically? Professor Guest’s response to this question sums it up well: “there have to be some criteria against which governments decide to allocate limited resources and money is one such criterion.” similarly, tan et al5 comment that economic evaluation “can play a useful role in assisting decision-makers, manage...

Insomnia is a leading cause of absenteeism, presenteeism (lost productivity when employees are at work), accidents, and errors in the workplace. Overall direct and indirect costs exceed $30 billion annually. A significant portion of these costs are attributable to patients with comorbid insomnia, making these conditions a significant clinical public health issue. These comorbid conditions inclu...

background: major thalassemia is an autosomal recessive disease with complications, mortality and serious pathology. today, the life expectancy of patients with major thalassemia has increased along with therapeutic advances. therefore, they need lifelong care, and caring for them would incur many costs. being aware of the patients’ costs can be effective for controlling and managing the costs ...